The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Current therapy for hilar cholelangiocarcinoma
Author(s): 
Pages: 165-168
Year: Issue:  3
Journal: Surgical Research and New Technique

Keyword:  肝门部胆管癌 治疗进展;
Abstract: 背景肝门区胆管癌(Hilar cholangiocarcinoma,HC)是源于肝外左右肝管或左右肝管汇合处的胆道腺癌,迄今对其治果不佳。本文通过相关文献回顾,综述肝门胆管癌的治疗方法、治疗时机选择和术前检查评估。其中,治愈性治疗包括局部切除、部分肝切除、联合尾状叶切除及肝门区淋巴结清扫、原位肝移植。局部切除仅适于局限于胆管壁及BismuthI级乳头状癌;对HC大部分选择部分肝切除联合尾状叶切除及肝门区淋巴结清扫。这些术式可根据门静脉栓塞,腹腔镜分期以及腹腔镜下超声等进行选择。但术前胆道引流存在争议;尽管Mayo指南中对无法切除的肝门胆管癌行原位肝移植的建议已被广泛接受,但肝门胆管癌自体移植结果令人失望。缓解治疗方案包括分流手术,内镜或经皮支架置入术,光动力学治疗,腔内短距离放射治疗,外照射治疗以及系统性化疗。结论恰当的R0切除是治疗的主要目标和选择,对无法切除的肝门胆管癌病人,治疗目标为改善生存质量。
Related Articles
No related articles found